News Website

Report finds ‘medical misogyny’ in treating gynaecological pain - Happiful Magazine

Report finds ‘medical misogyny’ in treating gynaecological pain Happiful Magazine

Published: Dec. 12, 2024, 11:54 a.m.

Read Full Article

Laura Barlow: Face-to-face GP appointments petition hits 100,000 - BBC.com

Laura Barlow: Face-to-face GP appointments petition hits 100,000 BBC.com

Published: Dec. 9, 2024, 8 p.m.

Read Full Article

Laura Barlow: Face-to-face GP appointments petition hits 100,000 - BBC

Laura Barlow: Face-to-face GP appointments petition hits 100,000 BBC

Published: Dec. 9, 2024, 3:54 p.m.

Read Full Article

Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News - StockTitan

Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News StockTitan

Published: Dec. 4, 2024, 12:01 a.m.

Read Full Article

Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News - StockTitan

Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News StockTitan

Published: Dec. 4, 2024, midnight

Read Full Article

NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer - OncLive

NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer OncLive

Published: Dec. 3, 2024, 5:11 p.m.

Read Full Article

Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast

Hutchmed endometrial cancer treatment gets conditional approval in China ShareCast

Published: Dec. 3, 2024, 10:28 a.m.

Read Full Article

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer GlobeNewswire

Published: Dec. 3, 2024, 10:01 a.m.

Read Full Article

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Canada Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Canada Finance

Published: Dec. 3, 2024, 10 a.m.

Read Full Article

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance

Published: Dec. 3, 2024, 10 a.m.

Read Full Article

Latest Articles

Report finds ‘medical misogyny’ in treating gynaecological pain - Happiful Magazine

Laura Barlow: Face-to-face GP appointments petition hits 100,000 - BBC.com

Laura Barlow: Face-to-face GP appointments petition hits 100,000 - BBC

Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News - StockTitan

Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News - StockTitan

NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer - OncLive

Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Canada Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance

Subscribe to Our Newsletter